NO20050294L - Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser - Google Patents

Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser

Info

Publication number
NO20050294L
NO20050294L NO20050294A NO20050294A NO20050294L NO 20050294 L NO20050294 L NO 20050294L NO 20050294 A NO20050294 A NO 20050294A NO 20050294 A NO20050294 A NO 20050294A NO 20050294 L NO20050294 L NO 20050294L
Authority
NO
Norway
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
NO20050294A
Other languages
English (en)
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/xx
Priority claimed from SE0202181A external-priority patent/SE0202181D0/xx
Priority claimed from SE0202908A external-priority patent/SE0202908D0/xx
Priority claimed from SE0300357A external-priority patent/SE0300357D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20050294L publication Critical patent/NO20050294L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Foreliggende oppfinnelse angår oppfinnelser med generell formel (1), hvori P er sulfon eller sulfonamid; og A, B, W, X, Y og R 3 er som definert i beskrivelsen; farmasøytiske sammensetninger innbefattende disse forbindelsene og anvendelsen av sammensetningene for profylakse og behandling av medisinske tilstander relatert til fedme, type II diabetes og/eller CNS-forstyrrelser, for å oppnå reduksjon av kroppsvekt og kroppsvektøkning.
NO20050294A 2002-06-20 2005-01-19 Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser NO20050294L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (sv) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (sv) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (sv) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (sv) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
NO20050294L true NO20050294L (no) 2005-02-04

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050294A NO20050294L (no) 2002-06-20 2005-01-19 Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser

Country Status (13)

Country Link
EP (1) EP1513828A1 (no)
CN (1) CN1662521A (no)
AU (1) AU2003243091A1 (no)
BR (1) BR0311952A (no)
CA (1) CA2486989A1 (no)
EA (2) EA011581B1 (no)
IL (1) IL165051A0 (no)
MX (1) MXPA04012914A (no)
NO (1) NO20050294L (no)
NZ (3) NZ552283A (no)
RS (1) RS111204A (no)
SG (1) SG156524A1 (no)
WO (1) WO2004000828A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209872B1 (pl) 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
CA2545506A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
CA2563895C (en) * 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
JP5270353B2 (ja) 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
AU2007263076A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
AU2007263075A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
AU2007263084A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP5872027B2 (ja) * 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
CA2158457C (en) * 1993-03-16 2001-04-17 Bertrand Leo Chenard Naphthalene derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
AU1542201A (en) * 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
CA2408156A1 (en) * 2000-05-05 2001-11-15 Millennium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
EP1326830A1 (en) * 2000-10-20 2003-07-16 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
CN1329382C (zh) * 2001-05-11 2007-08-01 比奥维特罗姆股份公司 治疗肥胖、ⅱ型糖尿病和cns－疾病的芳基磺酰胺化合物
JP4187642B2 (ja) * 2001-06-07 2008-11-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６受容体親和性を有する新規インドール誘導体
CA2445653A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Also Published As

Publication number Publication date
EP1513828A1 (en) 2005-03-16
CA2486989A1 (en) 2003-12-31
NZ552282A (en) 2008-07-31
BR0311952A (pt) 2005-04-19
AU2003243091A1 (en) 2004-01-06
WO2004000828A1 (en) 2003-12-31
NZ536600A (en) 2007-08-31
RS111204A (en) 2006-12-15
MXPA04012914A (es) 2005-03-31
EA008835B1 (ru) 2007-08-31
NZ552283A (en) 2008-07-31
EA200500054A1 (ru) 2005-06-30
SG156524A1 (en) 2009-11-26
CN1662521A (zh) 2005-08-31
EA200600975A1 (ru) 2006-10-27
IL165051A0 (en) 2005-12-18
EA011581B1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
NO20050294L (no) Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser
NO20075781L (no) Diarylsulfone-sulfonamider og deres anvendelse
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
SE0403006D0 (sv) New compounds
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
YU98003A (sh) Supstituisana sulfonamidna jedinjenja, postupak za njihovu upotrebu kao leka za tretiranje poremećaja cns, gojaznosti i dijabetesa tipa ii
NO20050828L (no) lndol-3-svovelderivater
AU2804400A (en) Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
WO2003028641A3 (en) Mch receptor antagonists
ATE385419T1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
NO20082496L (no) Pyrazinderivater
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20045042L (no) 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
NO20071222L (no) Benzamidforbindelser.
NO20076515L (no) Hydantoinforbindelser
NO20032841L (no) Heterocykloindol- eller azaindol-forbindelser som 5- hydroksytryptamin-6-ligander
NO20060718L (no) Substituerte tiofoner og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application